The International Neuromodulation SocietyThe Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of NeuromodulationThe International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, mentorship, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field. Donate TodayThe INS Peer-Reviewed JournalThe INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online. The journal also has social media accounts on Twitter, Facebook, and Instagram.
The Neuromodulation Podcast has been developed for our membership to dive into the forefront of today's emerging neuromodulation techniques, insights, and ethical and clinical applications. Join the multidisciplinary collaboration of medical care providers, scientists, and engineers who are part of the global conversation that's shaping the future of healthcare. Subscribe now wherever you get your podcasts. What is Neuromodulation?Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application. Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:
Breaking NewsStudy Links Depression Symptoms to Shifts in Prefrontal Brain Activity August 6, 2025 - A new study published in Nature Communications shows that fluctuations in depression symptoms are tied to low-frequency communication and hemispheric imbalances in the prefrontal cortex. The findings support theories that depression involves disrupted inhibitory control in brain networks and could guide the development of personalized neuromodulation therapies like adaptive deep brain stimulation. (Source: PsyPost) AI-Driven Models Help Personalize Deep Brain Stimulation to Improve Walking in Parkinson’s August 5, 2025 - Researchers from University of California, San Francisco (UCSF) used mathematical models and AI to predict personalized deep brain stimulation (DBS) settings that improved gait in people with Parkinson’s disease. The study showcased that tailoring DBS based on individual brain activity could improve walking performance, pointing toward more effective, individualized therapies. (Source: Parkinson's News Today) FDA Approves Vagus Nerve Stimulator for Rheumatoid Arthritis Treatment July 31, 2025 - The FDA has approved a vagus nerve stimulation device developed by SetPoint Medical for treating moderate-to-severe rheumatoid arthritis in patients unresponsive to biologic or targeted synthetic DMARDs. Implanted in the neck and activated for one minute daily, the device showed clinical benefits in a year-long trial, with plans for U.S. commercialization beginning in select US cities in late 2025. (Source: Medscape) Advances in Neuromodulation Techniques for Parkinson’s Disease Treatment July 30, 2025 - Advancements in invasive and non-invasive neuromodulation techniques, including Deep Brain Stimulation (DBS), transcranial stimulation, and focused ultrasound, are expanding treatment options for Parkinson’s disease by targeting both motor and non-motor symptoms. Emerging technologies like temporal interference, gene therapy, and nanoparticle-assisted drug delivery point toward a future of more personalized and adaptive therapies, though further clinical research is needed to confirm their long-term effectiveness. (Source: npj Parkinson's Disease) Vagus Nerve Stimulation Device Boosts Fitness Tolerance in Early Trial July 28, 2025 - A study published in the European Heart Journal found that using a vagus nerve stimulator for 30 minutes daily over one week improved oxygen uptake, heart rate, and breathing rate during exercise in healthy individuals. The device also reduced inflammation markers in the blood. According to researchers, the findings could pave the way for new therapies to help people with heart conditions improve their physical activity and well-being, pending further trials. (Source: Medical Xpress) Researchers Develop Advanced MRI Scanner to Map Microscopic Brain Structures in Living Humans July 16, 2025 - Scientists supported by the National Institutes of Health NIH developed a new system that noninvasively captures ultra-high-resolution images of microscopic brain structures in living humans. The scanner, called the Connectome 2.0 human MRI, enables researchers to map brain fibers and cellular architecture at nearly single-micron precision. (Source: Imaging Technology News) To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive. Continue Reading News Briefs |
